- Home
- POWW vs XFOR Comparison
POWW vs XFOR Comparison
Compare POWW & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POWW
- XFOR
- Stock Information
- Founded
- POWW 1990
- XFOR 2014
- Country
- POWW United States
- XFOR United States
- Employees
- POWW N/A
- XFOR N/A
- Industry
- POWW Ordnance And Accessories
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- POWW Industrials
- XFOR Health Care
- Exchange
- POWW Nasdaq
- XFOR Nasdaq
- Market Cap
- POWW 144.9M
- XFOR 118.4M
- IPO Year
- POWW N/A
- XFOR N/A
- Fundamental
- Price
- POWW $1.50
- XFOR $0.51
- Analyst Decision
- POWW Hold
- XFOR Strong Buy
- Analyst Count
- POWW 1
- XFOR 3
- Target Price
- POWW $1.50
- XFOR $3.50
- AVG Volume (30 Days)
- POWW 1.1M
- XFOR 2.9M
- Earning Date
- POWW 02-06-2025
- XFOR 11-13-2024
- Dividend Yield
- POWW N/A
- XFOR N/A
- EPS Growth
- POWW N/A
- XFOR N/A
- EPS
- POWW N/A
- XFOR N/A
- Revenue
- POWW $135,498,023.00
- XFOR $1,123,000.00
- Revenue This Year
- POWW $5.67
- XFOR N/A
- Revenue Next Year
- POWW $4.86
- XFOR $652.72
- P/E Ratio
- POWW N/A
- XFOR N/A
- Revenue Growth
- POWW N/A
- XFOR N/A
- 52 Week Low
- POWW $0.95
- XFOR $0.26
- 52 Week High
- POWW $2.94
- XFOR $1.60
- Technical
- Relative Strength Index (RSI)
- POWW 72.98
- XFOR 42.67
- Support Level
- POWW $1.30
- XFOR $0.43
- Resistance Level
- POWW $1.40
- XFOR $0.89
- Average True Range (ATR)
- POWW 0.10
- XFOR 0.09
- MACD
- POWW 0.03
- XFOR -0.04
- Stochastic Oscillator
- POWW 97.87
- XFOR 17.61
About POWW AMMO Inc.
AMMO Inc is the owner of GunBroker.com, the online marketplace serving the firearms and shooting sports industries, and a vertically integrated producer of high-performance ammunition and components. It engages in the design, manufacture, and market of ammunition products in the Shooting sports industry in the United States. The firm's product segment comprises Ammunition and Marketplace. The Ammunition segment engages in the design, production, and marketing of ammunition and ammunition component products and the marketplace segment consists of the GunBroker.com marketplace. The company generates the majority of its revenue from the Ammunition segment.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.